Quick Guide to Recent Changes We’ve Made to G2’s Reports
A new name comes with Lab Industry Advisor, but the goal of helping labs remains the same.
The latest regulatory, legal, compliance, and technology news for labs and pathology practices.
A new name comes with Lab Industry Advisor, but the goal of helping labs remains the same.
Q4 2022 financial results released by three key lab companies over the past week mainly included losses, but there were positives as well.
Influential panel cites lack of evidence of tests’ harms and benefits.
Last week saw the usual False Claims Act and kickback-related charges, with the biggest action involving urine drug testing.
FDA will still be able to issue EUAs for COVID-19 tests after May 11.
A new method of early, multi-cancer detection could prove more effective for non-invasive screening than other emerging options.
Cost cutting and restructuring has become the order of the day for many lab companies.
While AI as a diagnostic tool is still years away from regular clinical use, recent research is an important step.
Your current COVID-19 testing arrangements may no longer be compliant on May 11.
Most of last week’s healthcare-related actions involved telemedicine in some way, with the lone lab-related case centering on genetic testing.
Roche and Abbott received the most approvals for new lab tests last year.